Scienture Expands REZENOPY™ Access to 5,000 U.S. Institutions via GPO Deals
Event summary
- Scienture secured GPO agreements for REZENOPY™, covering over 5,000 U.S. healthcare institutions, including hospitals and EMS providers.
- The deals potentially penetrate ~60% of the U.S. institutional market for naloxone nasal spray.
- REZENOPY™, the highest-dose FDA-approved naloxone nasal spray, was commercialized under a March 2025 agreement with Summit Biosciences.
- The U.S. naloxone market totals $141M annually with 9.4M prescription units, per IQVIA data (MAT January 2026).
The big picture
Scienture's GPO agreements mark a strategic pivot toward institutional dominance in the naloxone market, capitalizing on the opioid crisis's urgency. The move aligns with broader trends of consolidation in emergency overdose treatments, where GPO partnerships drive scalability. With REZENOPY™'s highest-dose FDA approval, Scienture aims to outmaneuver rivals in a market where institutional procurement channels dictate growth.
What we're watching
- Market Share Capture
- How Scienture will leverage GPO partnerships to gain market share in the $141M U.S. naloxone market.
- Execution Risk
- Whether Scienture can sustain adoption rates across 5,000+ institutions post-GPO expansion.
- Competitive Dynamics
- The pace at which competitors respond to REZENOPY™'s institutional footprint growth.
Related topics